Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study

Aim: Lomitapide is an approved lipid-lowering agent indicated as adjunct to low-fat diet and standard lipid-lowering therapies (LLTs) including lipoprotein apheresis for the treatment of homozygous familial hypercholesterolemia (HoFH). Clinical data from Phase 3 studies have demonstrated the prolong...

Full description

Saved in:
Bibliographic Details
Published in:J Atheroscler Thromb
Main Authors: Nohara, Atsushi, Otsubo, Yoshihiko, Yanagi, Koji, Yoshida, Masayuki, Ikewaki, Katsunori, Harada-Shiba, Mariko, Jurecka, Agnieszka
Format: Artigo
Language:Inglês
Published: Japan Atherosclerosis Society 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6456458/
https://ncbi.nlm.nih.gov/pubmed/30259883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5551/jat.45708
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items